GSK gets expedited FDA review for multiple myeloma drug
The company anticipates the FDA to rule on the drug, belantamab mafodotin, in the first half of this year. If approved, it would be the first therapy targeting the cell-surface protein BCMA to hit the market. Several other anti-BCMA drugs are also in development.